default author photo

Yu-Peng Xue

Yunnan University

Kunming, 650091

China

SCHOLARLY PAPERS

1

DOWNLOADS

139

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Immunogenicity and Safety of a Recombinant gE-Fc Fusion Protein Subunit Vaccine for Herpes Zoster in Adults ≥50 Years of Age: A Randomised, Active-Controlled, Non-Inferiority Trial

Number of pages: 30 Posted: 09 Apr 2025
Chinese Center for Disease Control and Prevention (China CDC) - Jiangsu Provincial Center for Disease Control and Prevention, Government of the People's Republic of China - National Institutes for Food and Drug Control, Wuxi Centre for Disease Control and Prevention, Beijing Luzhu Biotechnology Co., Ltd., Chinese Center for Disease Control and Prevention (China CDC) - Jiangsu Provincial Center for Disease Control and Prevention, Nanjing Medical University, Wuxi Centre for Disease Control and Prevention, Beijing Luzhu Biotechnology Co., Ltd., Chinese Center for Disease Control and Prevention (China CDC) - Jiangsu Provincial Center for Disease Control and Prevention, Southeast University - School of Public Health, Government of the People's Republic of China - National Institutes for Food and Drug Control, Wuxi Centre for Disease Control and Prevention, Wuxi Centre for Disease Control and Prevention, Government of the People's Republic of China - National Institutes for Food and Drug Control, Government of the People's Republic of China - National Institutes for Food and Drug Control, Southeast University - School of Public Health, Southeast University - School of Public Health, Yunnan University, Yunnan University, Chinese Center for Disease Control and Prevention (China CDC) - Jiangsu Provincial Center for Disease Control and Prevention, Beijing Luzhu Biotechnology Co., Ltd., China Pharmaceutical University - State Key Laboratory of Natural Medicines, National Institutes for Food and Drug Control and Nanjing Medical University
Downloads 139 (527,599)

Abstract:

Loading...

Herpes zoster, gE-Fc fusion vaccine, subunit vaccine, immunogenicity, safety, non-inferiority trial